Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Observational Study in Cystic Fibrosis Patients With Chronic Respiratory Pseudomonas Aeruginosa Infection Treated With TOBI® PODHALER® (Tobramycin Inhalation Powder) or Other FDA Approved Inhaled Antipseudomonal Antibacterial Drugs

NCT02449031 is registered in ClinicalTrials.gov with Mylan Inc. as lead sponsor.

NCT NCT02449031
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02449031 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Observational Study in Cystic Fibrosis Patients With Chronic Respiratory Pseudomonas Aeruginosa Infection Treated With TOBI® PODHALER® (Tobramycin Inhalation Powder) or Other FDA Approved Inhaled Antipseudomonal Antibacterial Drugs
Lead sponsor
Mylan Inc.
Phase
Observational
Overall status
Completed
Start date
May 5, 2015
Completion date
December 31, 2021
Enrollment
409 (actual)
Sites
47

Conditions

As the registry lists them; a condition with its own page is linked.

pseudomonas aeruginosa in cystic fibrosis